pSivida announces resubmission of NDA for ILUVIEN pSivida Corp. (PSDV) announced that the New Drug Application for ILUVIEN for the treatment of chronic Diabetic Macular Edema has been resubmitted to the U.S. Food and Drug Administration. In the resubmission, pSivida’s licensee, Alimera Sciences (ALIM), responded to questions raised in the FDA’s October 2013 complete response letter and provided a safety update, which included commercial experience with ILUVIEN in Europe. Alimera is awaiting the FDA’s acceptance of the resubmission and a Prescription Drug User Fee Act date. pSivida will report that information when it becomes available.
News For PSDV;ALIM From The Last 14 Days
Check below for free stories on PSDV;ALIM the last two weeks.